Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (71)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Shibutani, S.
Right arrow Articles by Terashima, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shibutani, S.
Right arrow Articles by Terashima, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol 19, 2007-2011, Copyright © 1998 by Oxford University Press

ARTICLES

Sulfation of alpha-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts

S Shibutani, PM Shaw, N Suzuki, L Dasaradhi, MW Duffel and I Terashima
Department of Pharmacological Sciences, State University of New York at Stony Brook 11794-8651, USA. shinya@pharm.som.sunysb.edu

The formation of tamoxifen (TAM)-derived DNA adducts was investigated by incubation of DNA with (E)-alpha-hydroxytamoxifen [(E)-alpha-OHTAM], 3'-phosphoadenosine 5'-phosphosulfate (PAPS), and human recombinant sulfotransferase. Using 32P-post-labeling and HPLC analysis, two TAM- DNA adducts were detected in incubations that included the human hydroxysteroid sulfotransferase SULT2A1 (hHST). When compared with standards of stereoisomers of alpha-(N2-deoxyguanosinyl)tamoxifen 3'- monophosphate (dG3'P-N2-TAM), the major adduct was identified chromatographically as an epimer of the transform of dG-N2-TAM, and the minor adduct was identified as an epimer of the cis-form. The amount of TAM adducts formed by hHST was approximately three times less than that formed by an equivalent amount of rat hydroxysteroid (alcohol) sulfotransferase a. These results indicate that sulfation of alpha- OHTAM catalyzed by hHST results in the formation of dG-N2-TAMs, highly miscoding lesions, in human tissues.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
Z. Riches, E. L. Stanley, J. C. Bloomer, and M. W. H. Coughtrie
Quantitative Evaluation of the Expression and Activity of Five Major Sulfotransferases (SULTs) in Human Tissues: The SULT "Pie"
Drug Metab. Dispos., November 1, 2009; 37(11): 2255 - 2261.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
K. Brown
Is tamoxifen a genotoxic carcinogen in women?
Mutagenesis, September 1, 2009; 24(5): 391 - 404.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
Y. Alnouti
Bile Acid Sulfation: A Pathway of Bile Acid Elimination and Detoxification
Toxicol. Sci., April 1, 2009; 108(2): 225 - 246.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
I. Echchgadda, C. S. Song, T. Oh, M. Ahmed, I. J. De La Cruz, and B. Chatterjee
The Xenobiotic-Sensing Nuclear Receptors Pregnane X Receptor, Constitutive Androstane Receptor, and Orphan Nuclear Receptor Hepatocyte Nuclear Factor 4{alpha} in the Regulation of Human Steroid-/Bile Acid-Sulfotransferase
Mol. Endocrinol., September 1, 2007; 21(9): 2099 - 2111.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Brown, E. M. Tompkins, D. J. Boocock, E. A. Martin, P. B. Farmer, K. W. Turteltaub, E. Ubick, D. Hemingway, E. Horner-Glister, and I. N.H. White
Tamoxifen Forms DNA Adducts in Human Colon after Administration of a Single [14C]-Labeled Therapeutic Dose
Cancer Res., July 15, 2007; 67(14): 6995 - 7002.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
P A Sinclair, W J Gilmore, Z Lin, Y Lou, and E J Squires
Molecular cloning and regulation of porcine SULT2A1: relationship between SULT2A1 expression and sulfoconjugation of androstenone.
J. Mol. Endocrinol., April 1, 2006; 36(2): 301 - 311.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
C. S. Song, I. Echchgadda, Y.-K. Seo, T. Oh, S. Kim, S.-A Kim, S. Cho, L. Shi, and B. Chatterjee
An Essential Role of the CAAT/Enhancer Binding Protein-{alpha} in the Vitamin D-Induced Expression of the Human Steroid/Bile Acid-Sulfotransferase (SULT2A1)
Mol. Endocrinol., April 1, 2006; 20(4): 795 - 808.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Y. Kim, N. Suzuki, Y. R. S. Laxmi, and S. Shibutani
INEFFICIENT REPAIR OF TAMOXIFEN-DNA ADDUCTS IN RATS AND MICE
Drug Metab. Dispos., February 1, 2006; 34(2): 311 - 317.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Y. Kim, Y. R. S. Laxmi, N. Suzuki, K. Ogura, T. Watabe, M. W. Duffel, and S. Shibutani
FORMATION OF TAMOXIFEN-DNA ADDUCTS VIA O-SULFONATION, NOT O-ACETYLATION, OF {alpha}-HYDROXYTAMOXIFEN IN RAT AND HUMAN LIVERS
Drug Metab. Dispos., November 1, 2005; 33(11): 1673 - 1678.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. I. Apak and M. W. Duffel
INTERACTIONS OF THE STEREOISOMERS OF {alpha}-HYDROXYTAMOXIFEN WITH HUMAN HYDROXYSTEROID SULFOTRANSFERASE SULT2A1 AND RAT HYDROXYSTEROID SULFOTRANSFERASE STA
Drug Metab. Dispos., December 1, 2004; 32(12): 1501 - 1508.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
F. A. Beland, M. I. Churchwell, D. R. Doerge, D. R. Parkin, D. Malejka-Giganti, A. Hewer, D. H. Phillips, P. L. Carmichael, G. Gamboa da Costa, and M. M. Marques
Electrospray Ionization-Tandem Mass Spectrometry and 32P-Postlabeling Analyses of Tamoxifen-DNA Adducts in Humans
J Natl Cancer Inst, July 21, 2004; 96(14): 1099 - 1104.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
M.E. Heres-Pulido, I. Duenas-Garcia, L. Castaneda-Partida, A. Sanchez-Garcia, M. Contreras-Sousa, A. Duran-Diaz, and U. Graf
Genotoxicity of tamoxifen citrate and 4-nitroquinoline-1-oxide in the wing spot test of Drosophila melanogaster
Mutagenesis, May 1, 2004; 19(3): 187 - 193.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
I. Echchgadda, C. S. Song, A. K. Roy, and B. Chatterjee
Dehydroepiandrosterone Sulfotransferase Is a Target for Transcriptional Induction by the Vitamin D Receptor
Mol. Pharmacol., March 1, 2004; 65(3): 720 - 729.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Shibutani, N. Suzuki, Y. R. S. Laxmi, L. J. Schild, R. L. Divi, A. P. Grollman, and M. C. Poirier
Identification of Tamoxifen-DNA Adducts in Monkeys Treated with Tamoxifen
Cancer Res., August 1, 2003; 63(15): 4402 - 4406.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. J. Sheng and M. W. Duffel
ENANTIOSELECTIVITY OF HUMAN HYDROXYSTEROID SULFOTRANSFERASE ST2A3 WITH NAPHTHYL-1-ETHANOLS
Drug Metab. Dispos., June 1, 2003; 31(6): 697 - 700.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Z. Duanmu, D. Locke, J. Smigelski, W. Wu, M. S. Dahn, C. N. Falany, T. A. Kocarek, and M. Runge-Morris
Effects of Dexamethasone on Aryl (SULT1A1)- and Hydroxysteroid (SULT2A1)-Sulfotransferase Gene Expression in Primary Cultured Human Hepatocytes
Drug Metab. Dispos., September 1, 2002; 30(9): 997 - 1004.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
T. Kasahara, M. Hashiba, T. Harada, and M. Degawa
Change in the gene expression of hepatic tamoxifen-metabolizing enzymes during the process of tamoxifen-induced hepatocarcinogenesis in female rats
Carcinogenesis, March 1, 2002; 23(3): 491 - 498.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
G. Gamboa da Costa, L.P. McDaniel-Hamilton, R. H. Heflich, M.M. Marques, and F. A. Beland
DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives
Carcinogenesis, August 1, 2001; 22(8): 1307 - 1315.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. H. Phillips
Understanding the genotoxicity of tamoxifen?
Carcinogenesis, June 1, 2001; 22(6): 839 - 849.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Shibutani, A. Ravindernath, I. Terashima, N. Suzuki, Y. R. Santosh Laxmi, Y. Kanno, M. Suzuki, T. I. Apak, J. J. Sheng, and M. W. Duffel
Mechanism of Lower Genotoxicity of Toremifene Compared with Tamoxifen
Cancer Res., May 1, 2001; 61(10): 3925 - 3931.
[Abstract] [Full Text]

Home page
 CarcinogenesisHome page
D. J. Boocock, J. L. Maggs, K. Brown, I. N.H. White, and B.K. Park
Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of {alpha}-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts
Carcinogenesis, October 1, 2000; 21(10): 1851 - 1858.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. Umemoto, Y. Monden, M. Suwa, Y. Kanno, M. Suzuki, C.-X. Lin, Y. Ueyama, Md.A. Momen, A. Ravindernath, S. Shibutani, et al.
Identification of hepatic tamoxifen-DNA adducts in mice: {alpha}-(N2-deoxyguanosinyl)tamoxifen and {alpha}-(N2-deoxyguanosinyl)tamoxifen N-oxide
Carcinogenesis, September 1, 2000; 21(9): 1737 - 1744.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. Shibutani, A. Ravindernath, N. Suzuki, I. Terashima, S. M. Sugarman, A. P. Grollman, and M. L. Pearl
Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen
Carcinogenesis, August 1, 2000; 21(8): 1461 - 1467.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Davis, A. Hewer, K. M. Rajkowski, W. Meinl, H. Glatt, and D. H. Phillips
Sex Differences in the Activation of Tamoxifen to DNA Binding Species in Rat Liver in Vivo and in Rat Hepatocytes in Vitro: Role of Sulfotransferase Induction
Cancer Res., June 1, 2000; 60(11): 2887 - 2891.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Shibutani, J. T. Reardon, N. Suzuki, and A. Sancar
Excision of Tamoxifen-DNA Adducts by the Human Nucleotide Excision Repair System
Cancer Res., May 1, 2000; 60(10): 2607 - 2610.
[Abstract] [Full Text]

Home page
 CarcinogenesisHome page
H. Bartsch, D. H. Phillips, J. Nair, A. Hewer, G. Meyberg-Solomeyer, and E.-M. Grischke
Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients
Carcinogenesis, April 1, 2000; 21(4): 845 - 847.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. M. J. J. Berns, J. A. Foekens, R. Vossen, M. P. Look, P. Devilee, S. C. Henzen-Logmans, I. L. van Staveren, W. L. J. van Putten, M. Inganäs, M. E. M.-v. Gelder, et al.
Complete Sequencing of TP53 Predicts Poor Response to Systemic Therapy of Advanced Breast Cancer
Cancer Res., April 1, 2000; 60(8): 2155 - 2162.
[Abstract] [Full Text]

Home page
 CarcinogenesisHome page
D. H. Phillips, A. Hewer, M. N. Horton, K. J. Cole, P. L. Carmichael, W. Davis, and M. R. Osborne
N-Demethylation accompanies {alpha}-hydroxylation in the metabolic activation of tamoxifen in rat liver cells
Carcinogenesis, October 1, 1999; 20(10): 2003 - 2009.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
I. N.H. White
The tamoxifen dilemma
Carcinogenesis, July 1, 1999; 20(7): 1153 - 1160.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Terashima, N. Suzuki, and S. Shibutani
Mutagenic Potential of {{alpha}}-(N2-Deoxyguanosinyl)tamoxifen Lesions, the Major DNA Adducts Detected in Endometrial Tissues of Patients Treated with Tamoxifen
Cancer Res., May 1, 1999; 59(9): 2091 - 2095.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.